Handling Waivers for In Vivo Bioequivalence Studies: Regulatory Strategies and Criteria
Handling Waivers for In Vivo Bioequivalence Studies: Regulatory Strategies and Criteria Strategic Guide to Obtaining Waivers for In Vivo Bioequivalence Studies Introduction: Why Waive In Vivo BE Studies? In vivo bioequivalence (BE) studies are time-consuming, expensive, and sometimes unnecessary—particularly for drugs that meet specific regulatory criteria for waivers. Regulatory agencies like the FDA and EMA…